Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Pembrolizumab stories

Nov 13, 2026

FDA approves durvalumab plus enfortumab vedotin for muscle-invasive bladder cancer

The FDA approved AstraZeneca's durvalumab combined with enfortumab vedotin as neoadjuvant treatment followed by adjuvant durvalumab after radical cystectomy for muscle-invasive bladder cancer. The approval adds a new perioperative immunotherapy option for this high-risk cancer.

Nov 13, 2026·2 sources
00
Sep 21, 2026

Ivonescimab extends survival vs pembrolizumab in PD-L1+ advanced NSCLC trial

First-line ivonescimab significantly prolonged overall survival compared with pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer, according to updated analysis from a clinical trial.

Sep 21, 2026·2 sources
00

Top claims

  • ▪In the phase 3 VOLGA trial, neoadjuvant durvalumab plus enfortumab vedotin achieved an estimated 24-month event-free survival rate of 63.5% compared to 45.1% with radical cystectomy alone
  • ▪In the phase 3 VOLGA trial, grade 3 or higher adverse events occurred in 71.1% of muscle-invasive bladder cancer patients receiving durvalumab plus enfortumab vedotin compared to 50.2% undergoing surgery alone
  • ▪In the phase 3 VOLGA trial, pathologic complete response by local review was achieved in 45.1% of patients receiving durvalumab plus enfortumab vedotin versus 9.6% with radical cystectomy alone

Topics

FDA drug approvalCancer treatmentCancer & OncologyClinical trialsCancer and Cancer TreatmentCancer treatment breakthroughsCancer immunotherapyDrug Policy, Pricing & ApprovalOncologyImmunotherapyDrug Approval and Clinical TrialsClinical evaluationClinical Trial Design & Evaluation

Related entities

DurvalumabNon-small cell lung cancerLung cancer